Marker Therapeutics (MRKR) filed a registration statement Wednesday for the potential sale of up to $300 million of securities from time to time in one or more offerings.
The filing covers the sale of the company's common and preferred shares, debt securities and warrants.
Proceeds from the offering will be used for working capital, capital expenditures and general corporate purposes, according to the company.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments